Indolent Lymphoma
Conference Coverage
Early results favor combo IL-15/anti-CD20 in indolent NHL
CHICAGO – The researchers tested the combination of rituximab with the IL-15 receptor super agonist complex ALT-803.
From the Journals
Venetoclax shows muscle against CLL relapsed after idelalisib
The BCL-2 inhibitor venetoclax may be an effective follow-on to a B cell receptor pathway inhibitor.
News from the FDA/CDC
FDA grants priority review of follicular lymphoma drug
The target date for FDA action is Oct. 5, 2018.
From the Journals
Updated CLL guidelines incorporate a decade of advances
Advances in genomics, diagnostics and therapies since 2008 are reflected in the guidelines.
News
FDA updates breast implant–associated lymphoma cases, risk
Estimates on the lifetime risk vary widely.
From the Journals
Ibrutinib linked to invasive fungal infections
The researchers called for greater awareness of the potential for fungal infection in ibrutinib-treated patients.
Conference Coverage
Mycosis fungoides increases risk for second cancers
LA JOLLA, CALIF. – The study mines data from the SEER-18 database.
Conference Coverage
High objective response rate, OS seen with ATA129 in PTLD
SALT LAKE CITY, UTAH – The findings confirm those from prior single-center studies.
From the Journals
Triple therapy ups response in refractory mantle cell lymphoma
The results show that triple therapy with ibrutinib, lenalidomide, and rituximab should be evaluated in a randomized controlled trial.
From the Journals
Background color a dermoscopic clue to cutaneous B-cell lymphoma
On dermoscopy, almost 80% of the lesions showed salmon- or yellow- to orange-colored background areas.
Conference Coverage
VIDEO: Practice changers out of ASH 2017
ATLANTA – Dr. Robert Brodsky shares his takeaways on the key practice changing data presented in the ASH 2017 late breakers.